Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Rituximab for Peripheral Neuropathy Associated With Monoclonal Gammopathy of Undetermined Significance (MGUS)

NCT00588822 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT00588822
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00588822 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Rituximab for Peripheral Neuropathy Associated With Monoclonal Gammopathy of Undetermined Significance (MGUS)
Lead sponsor
Mayo Clinic
Phase
Phase 2
Overall status
Terminated
Start date
January 31, 2005
Completion date
February 28, 2011
Enrollment
21 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

precancerous condition